Kornimate/medical-research-clean huggingface dataset:
very early surfactant and ncpap for premature infants with rds

Conditions: Respiratory Distress Syndrome; Pneumothorax/Pulmonary Intersticial Emphysema; Chronic Lung Disease

Summary: the present study will test the use of very early nasal continuous airway pressure(ncpap)with and without surfactant in premature infants with clinical evidence or respiratory distress syndrome. we hypothesize that premature infants exposed to very early ncpap and surfactant will require less mechanical ventilation compared to those premature infants exposed to ncpap alone.

premature infants who are not intubated during the first 15 minutes of life and who develop clinical evidence of respiratory distress or need for oxygen requirement between 15 and 60 minutes of life, will be placed on bubble ncpap of 6 cm h2o. randomization envelops will them be opened and patients will be assigned to continuation on ncpap alone (control group) or to ncpap plus very early surfactant therapy (treatment group). patients assigned to the treatment group will be transiently intubated for surfactant administration, extubated, and placed back on ncpap of 6 cm h2o. both groups will then be followed over time to determine which infants meet treatment failure criteria defined as: treatment failure was defined a priori by either failure of adequate oxygenation or ventilation as follows: "1" fio2 greater than 0.75 for more than 30 minutes to maintain spo2 within the pre-established target ranges, "2" persistent or recurrent desaturation below 80% that did not respond to suctioning of the airways and ppv, "3" pco2\>65 mmhg and ph\<7.22 on an arterial or capillary blood gas analysis, in association with increased work of breathing. infants in the treatment group who cannot be extubated after their initial dose of surfactant because of clinical instability will be analyzed as treatment failures. premature infants that meet treatment failure criteria on either arm will be intubated and placed on mechanical ventilation and given surfactant rescue doses according to the criteria of the participating institutions. premature infants with respiratory distress syndrome who do not meet treatment failure criteria in both groups will remain on ncpap until their respiratory failure improves.

Eligibility criteria:
inclusion criteria: * gestational age of 27 to 31 6/7 weeks, * postnatal age between 15 and 60 minutes, * supplemental oxygen requirement or evidence of increased work of breathing (tachypnea, intercostal retractions, nasal flaring, or grunting), and * prenatal consent. exclusion criteria: * apgar score less than 2 at 5 minutes, * intubation prior to randomization, * prenatal diagnosis of major congenital anomalies, * prolonged rupture of membranes of greater than 3 weeks duration, and * infants who were likely to be transferred to another center soon after birth were not enrolled in the study.

Keywords: ncpap very early surfactant
trial of using sib-imrt in preoperative radiotherapy for locally advanced rectum cancer

Conditions: Rectal Cancer

Summary: pathological complete response, (pcr) correlates with a favorable overall prognosis in locally advanced rectal cancer patients underwent preoperative chemoradiation, so obtaining a pcr might be beneficial. the aim of the study is to investigate safety and efficacy of preoperative sib-imrt(56gy) combine with capecitabine. primary endpoint is pathological complete remission rate.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed rectal adenocarcinoma with an inferior border within 15 cm of the anal verge * the tumor has to have evidence of t3 or t4 disease on magnetic resonance imaging (mri) or endoluminal ultrasound exclusion criteria: * metastatic disease * eastern cooperative oncology group (ecog) performance status \> 3 * patients not deemed fit for radiotherapy, capecitabine or surgery * pregnant or lactating patients * women with child bearing potential who lack effective contraception * patients below 18 years old

Keywords: preoperative chemoradiotherapy locally advanced rectal cancer boost imrt
observational study to characterize biomarkers and disease progression in participants with methyl cpg binding protein 2 (mecp2) duplication syndrome

Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Summary: the purpose of the study is to prospectively assess longitudinal changes in biomarkers (mecp2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (csf) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of neurodevelopment and functioning) and caregiver-reported outcome assessments (communication, gastrointestinal, social-emotional-adaptive behavioral measures); evaluate longitudinal changes in caregiver-reported health-related quality-of-life measures; and assess the frequency, type, and severity of seizures over time.

this is a multi-center, non-randomized, non-interventional prospective and retrospective study in up to 40 participants with mecp2 duplication syndrome (mds) who can undergo general anesthesia or conscious sedation to collect fluid biomarkers (csf and blood), undergo electrophysiological assessments (electroencephalogram \[eeg\], evoked potentials \[ep\], pupillometry), clinical assessments and caregiver reported outcomes measures, to be used in support of the development of therapies for mds. the study duration for each participant will be approximately 110 weeks.

Eligibility criteria:
key inclusion criteria * participant has a diagnosis of mds with genetic confirmation of mecp2 duplication (or triplication) * participant has a parent or caregiver (cg) ≥ 18 years old capable of providing informed consent (signed and dated), and able to attend all scheduled study visits and provide feedback regarding the participant's symptoms and performance as described in the protocol and be able to comply with all study requirements and activities * male ≥ 1 month and ≤ 65 years of age * no contraindications for lumbar puncture (lp)'s, blood draws, sedation (if necessary) or other study activities * medically stable to complete the study and will tolerate sedation or general anesthesia and other study activities key exclusion criteria * clinically significant abnormalities in medical history (e.g., clinically significant renal, hepatic, or cardiac abnormalities; major surgery within 3 months of screening) or upon physical examination that could potentially impact the nh of mds * unwillingness or inability to comply with study procedures, including follow up, as specified by this protocol, or unwillingness to cooperate fully with the investigator * treatment with an investigational drug, gene therapy, stem cell therapy, biological agent, or device within 30 days of screening, or 5 half-lives of investigational agent, whichever is longer (participants cannot be concurrently enrolled in nh00006 and ion440-cs1).

Keywords: mds
inhalation intervention for nausea in the emergency department

Conditions: Nausea; Vomiting

Summary: randomized controlled trial comparing inhalation of isopropyl alcohol vs placebo (normal saline) pads to treat nausea in emergency department patients.

this study is to investigate if inhaling the scent of a typical medical alcohol prep pad will alleviate nausea as compared to a identically packaged normal saline prep pad for the emergency department patient with nausea. the study length will be 10 minutes long. the subjects will take several deep nasal inhalations at the 0, 2, 5 minute marks. level of nausea will be recorded during these times and at 10 minutes. the investigators will also assess satisfaction of the intervention. as in previous post operative unit studies,the hypothesis is that there will a significant difference in levels of nausea between the alcohol pad group versus the normal saline pad group.

Eligibility criteria:
inclusion criteria: * age range of 18-65 years of age * complaint of nausea and or vomiting * ability to breathe through nose * ability to read and write english exclusion criteria: * allergy to isopropyl alcohol * pregnancy or pregnancy status unknown to subject. pregnancy test only if part of clinical course. * recent upper respiratory infection * recent intake of cefoperazone, disulfiram, or metronidazole or any other medications that are known produce nausea when exposed to alcohol. * use of antiemetic or psychoactive drug within 24 hours * alcohol abuse * nicotine within last 4 hrs

Keywords: nausea vomiting antiemetic
clinical trial to evaluate two guidelines for the administration of ibuprofen in the treatment of persistent ductus arteriosus eco-guided: impact in the intestinal prognosis

Conditions: Persistent Ductus Arteriosus

Summary: persistent ductus arteriosus (da) is a common entity in the premature newborn and is associated with high morbidity and mortality. there is still controversy about which is the best treatment for its closure. children with ad who receive pharmacological treatment present more frequently than other premature children, necrotizing enterocolitis or isolated intestinal perforation. at the present time, the conventional treatment of da consists in the administration of intravenous ibuprofen, slow bolus in 3 daily doses 10-5-5 mg / kg / day. recently, it has been observed that treatment with ibuprofen in continuous iv infusion for 3 days seems to be more effective in closing da than conventional treatment for 3 days with the same dose but in slow iv bolus. this experimental treatment reduced the incidence of associated necrotizing enterocolitis. our group demonstrated in a previous pilot trial that the guided treatment with echocardiography (echog) of da with ibuprofen compared with conventional treatment, allows to reduce the number of doses to the patient. the echog treatment thus presents a potential reduction of side effects associated with medication, this resulted in a tendency to have a lower incidence of necrotising enterocolitis in the experimental group. this multicenter clinical trial aims to test the hypothesis that the combination of 2 experimental treatments, the use of ibuprofen in continuous perfusion and echog, reduces the incidence of digestive side effects (necrotising enterocolitis or isolated intestinal perforation) compared to the treatment also guided by echocardiography but slow bolus iv.


Eligibility criteria:
inclusion criteria: * preterm infants with less 33 weeks of gestational age * da ≥ 1.5 mm with decision to start pharmacological treatment * informed consent signed by the legal representative exclusion criteria: * consent denied * presence of serious congenital alterations * congenital heart disease * contraindication for the administration of ib: oligoanuria (diuresis \ 1.5 mg / dl or clinical suspicion of intestinal ischemia.
efficacy of fluocinolone acetonide intravitreal implant in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: this was a multi-center, randomized, masked, parallel-group, controlled study in patients with diabetic macular edema, comparing retiserttm (0.59 mg) with control therapy (standard of care (soc) - repeat macular grid laser or observation). the objective was to evaluate the safety and efficacy of the intravitreal fluocinolone acetonide implant in the treatment of patients with diabetic macular edema.


Eligibility criteria:
inclusion criteria: * males and nonpregnant females at least 18 years of age, with dme in the study eye * edema must involve fixation and be at least 1 disc area in size * visual acuity of ≥20 and ≤68 letters by etdrs in the study eye * the study eye must have received at least one macular laser treatment \> 12 weeks prior to entry into the study * ability and willingness to comply with treatment and follow-up * ability to understand and sign the informed consent form exclusion criteria: * pregnant, lactating females * allergy to fluocinolone acetonide or any component of the delivery system * any disease or condition that would preclude study treatment or follow up * presence at screening of iop greater or equal to 22 mm hg while on antiglaucoma medication(s). * history of uncontrolled iop within the last 12 months
expressive writing on stress and work-related outcomes among student nurse interns

Conditions: Stress, Psychological

Summary: the goal of this interventional study is to assess the effects of an intervention on stress and work-related outcomes among chinese student nurse interns. the main questions it aims to answer are: * does expressive writing reduce clinical practice stress and improve coping strategies in student nurse interns? * does expressive writing increase work engagement and perceived professional benefit among student nurse interns? participants in the intervention group and control group will perform expressive writing and neutral writing, respectively, based on different given instructions. in both groups, writing will last for 15 minutes each time, twice a week, for ten weeks. researchers will compare the outcomes of the two groups to see if there are differences between clinical practice stress, coping strategies, work engagement, and perceived professional benefit.


Eligibility criteria:
inclusion criteria: * undergraduate student nurse interns in their first clinical internship (had no prior clinical practice experience) * have access to and proficiency in utilizing social media * be able to read and write via the internet * be willing to fill in questionnaires and write according to the assigned writing prompts * never participated in expressive writing or stress management intervention programs exclusion criteria: * intern at a self-contacted hospital * severe current psychological conditions * undergoing any form of psychotherapy * with a habit of keeping diaries withdrawal criteria: * termination of internship for whatever reason * not submit writing materials twice
technology assisted treatment for binge eating behavior

Conditions: Binge-Eating Disorder

Summary: binge-eating behavior is a central feature of eating disorders (e.g., binge-eating disorder, bulimia nervosa, anorexia nervosa-binge-eating/purging subtype) and is associated with higher rates of psychopathology, psychosocial impairment, medical comorbidity, and more severe obesity, all of which pose significant public health problems. passive detection of binge eating episodes combined with a context-based reminder intervention could assist a patient in resuming healthy eating patterns. this study will test a smartwatch app that identifies binge eating behavior and provides cbt strategies to the patient after the episode.


Eligibility criteria:
inclusion criteria: 1. adults ≥18 years of age 2. ede diagnosis of bulimia nervosa or binge eating disorder, with binge-eating episodes occurring at least 2x/week exclusion criteria: 1. pregnancy or lactation 2. acute medical or psychiatric risk 3. psychosis or bipolar disorder (lifetime history) 4. current substance use disorder within the past six months 5. bmi less than 18.5 kg/m2 6. acute suicidality requiring hospitalization 7. food allergies 8. receiving current psychotherapy 9. on psychotropic medications that have not been on a stable dose for at least six weeks
a study comparing clindamycin phosphate, adapalene, and benzoyl peroxide topical gel 0.15%;3.1%;1.2% (taro pharmaceuticals u.s.a., inc.) and cabtreo topical gel for the treatment of acne vulgaris.

Conditions: Acne Vulgaris

Summary: to demonstrate the efficacy, therapeutic equivalence and safety of clindamycin phosphate, adapalene, and benzoyl peroxide topical gel 0.15%;3.1%;1.2% (taro pharmaceuticals u.s.a., inc.) and cabtreo topical gel in the treatment of acne vulgaris.

a multi-center, double-blind, randomized, placebo-controlled, parallel-group study, comparing clindamycin phosphate, adapalene, and benzoyl peroxide topical gel 0.15%;3.1%;1.2% to cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel in the treatment of acne vulgaris.

Eligibility criteria:
inclusion criteria: * healthy male or nonpregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris. * subjects who are 18 years of age or older must have provided irb approved written informed consent. * subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3 or 4 as per the investigator's global assessment (iga). * subjects must have ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) and ≥ 20 inflammatory lesions (i.e., papules and pustules) and ≤2 nodulocystic lesions (i.e., nodules and cysts), at baseline on the face. exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation. * subjects with a history of hypersensitivity or allergy to clindamycin phosphate, benzoyl peroxide, adapalene, retinoids and/or any of the study medication ingredients. * subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis). * subjects with excessive facial hair (e.g. beards, sideburns, mustaches, etc.) that would interfere with the diagnosis or assessment of acne vulgaris.
development of a modified pediatric early warning score: a french prospective multicentre regional study

Conditions: Critical Illness

Summary: children are admitted in intermediate units when the severity requires continuous monitoring. in france, resources allocated to intermediate units are determined from lists of diagnoses and associated acts to additional budget. a score to assess the severity of illness may be associated with acts to develop an activity indicator easy to use. the investigators have chosen 2 scores to assess severity in intermediate cares : the paediatric advanced warning score (paws) and the bedside pediatric early system score (pews). in france, they have not been validated. the correlation between the severity of children and the associated diagnoses and acts has not been studied. the main objective of this study is to validate these 2 scores. the secondary objective is to determine a simplified activity indicator.


Eligibility criteria:
inclusion criteria: * all children admitted to the paediatric inpatient unit exclusion criteria: * parental refusal

Keywords: critical illness disease progression child severity of illness index monitoring
diagnostic interview and one-session cognitive therapy in treatment of dental fear

Conditions: Dental Fear

Summary: clinical trial of an application of cognitive behavioural one-session therapy method with patients who have severe or average dental fear/anxiety measured by modified dental anxiety scale (mdas). the intervention consists of two different parts: a diagnostic interview and one-session treatment of dental care. the method is based on one-session therapy manual (öst \& skaret, 2013). 30 minimum 18 years old adults takes part to the study. they comes from three different places,primary care clinic, community dental care and dentist´s teaching clinic.

purpose is to compare diagnostic interview (n=20) to diagnostic interview and one-session treatment of dental care (n=10). partners come from three different places, 10 from each: public and private dental care and dental school. participants from dental school take part to one-session treatment. all participants have normal dental care before final interview. hypotheses is that dental fear/anxiety will decrease one category (5 points) when measured by modified dental anxiety scale (mdas) before the intervention and after normal dental care. visual analogue scale is used to measure the strength of unpleasant feeling before and after intervention in both groups.

Eligibility criteria:
inclusion criteria: * mdas 13 or over, dental care in normal circumstances doesn´t work, motivation to treat dental fear, minimum 18 year exclusion criteria: * mental disorder, dementia, pregnancy, acute state of somatic illness

Keywords: dental anxiety cognitive therapy
reliability of artificial intelligence (ai)-augmented point-of-care cardiac ultrasound in the hands of internists

Conditions: Cardiovascular Diseases; Valvular Heart Disease

Summary: the study aim is to test the diagnostic performance of internists interpreting echo images aided by the aisap cardio v0.7 diagnostic support system. ground truth will be established by an interpretation by cardiologists specialized in echo, of the same pocus images (acquired by the internist \\ sonographer ). up to 1000 subjects; study population will be distributed according to the following schema: group 1 -up to 800 patients hospitalized in the internal medicine division group 2 - up to 200 patients hospitalized in the acute geriatric division


Eligibility criteria:
inclusion criteria: 1. clinically indicated pocus cardiac assessment as determined by the treating physicians for an accepted clinical indication 2. willing and able to provide consent for a short partial transthoracic poccus examinations 3. no urgent or other compelling need for a comprehensive echo exam by the echo lab. exclusion criteria: 1. unstable clinical condition that does not permit any reasonable delay necessary to obtain consent and perform the poccus 2. severe thoracic deformation or thoracic wall infection or wound that does not permit an adequate echocardiographic examination 3. very poor or non-diagnostic echocardiographic imaging quality on prior echocardiography examinations. 4. patients after lung resection 5. patients unable lie in bed and undergo a standard echo study 6. participation in an interventional study